专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050153329A1 Method for determining immune system affecting compounds 审中-公开
标题翻译：确定免疫系统影响化合物的方法
公开(公告)号：US20050153329A1
公开(公告)日：2005-07-14
申请号：US10997985
申请日：2004-11-29
申请人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
IPC分类号： A61K35/12 , A61K39/00 , C07K16/28 , C12Q1/68 , G01N33/574
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/54 , C07K2317/73 , C07K2317/76 , G01N33/574 , G01N2800/52
摘要： The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations.
摘要翻译：本发明涉及一种提高癌症疗效和/或治疗可能性的方法，其中包括一种或多种细胞因子（包括IL-1β）的产生免疫调节物质的任何功能调节机制，包括诱导因子，IL-1Ra，IL-6，IL-10，IL-17，TNF-α等治疗控制，以最小化这种免疫调节物质的病理生产，以增强患有恶性肿瘤的恶性肿瘤的治疗控制癌症，分析调节机制的物质的方法，用于分析的试剂盒，用于制备药物制剂的某些化合物的使用以及药物制剂。

2. 发明授权

US08182983B2 Method for determining immune system affecting compounds 有权
标题翻译：确定免疫系统影响化合物的方法
公开(公告)号：US08182983B2
公开(公告)日：2012-05-22
申请号：US12822013
申请日：2010-06-23
申请人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
IPC分类号： C12Q1/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/54 , C07K2317/73 , C07K2317/76 , G01N33/574 , G01N2800/52
摘要： The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations.
摘要翻译：本发明涉及一种提高癌症治疗效果和/或可能性的方法，其中包括一种或多种细胞因子（包括IL-1和bgr）的免疫调节物质的产生的任何功能调节机制，包括诱导因子 ; IL-1Ra，IL-6，IL-10，IL-17，TNF-α等治疗控制，以使这种免疫调节物质的病理生产最小化，以增强受试者中恶性肿瘤的治疗控制来自癌症的方法，用于分析调控机制的物质的分析方法，用于分析的试剂盒，用于制备药物制剂的某些化合物的使用以及药物制剂。

3. 发明申请

US20100323370A1 METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS 有权
标题翻译：用于确定影响化合物的免疫系统的方法
公开(公告)号：US20100323370A1
公开(公告)日：2010-12-23
申请号：US12822013
申请日：2010-06-23
申请人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Annika Hakansson , Birgitta Clinchy
IPC分类号： G01N33/574 , G01N33/53
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/54 , C07K2317/73 , C07K2317/76 , G01N33/574 , G01N2800/52
摘要： The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations.
摘要翻译：本发明涉及一种提高癌症治疗效果和/或可能性的方法，其中包括一种或多种细胞因子（包括IL-1和bgr）的免疫调节物质的产生的任何功能调节机制，包括诱导因子 ; IL-1Ra，IL-6，IL-10，IL-17，TNF-α等治疗控制，以使这种免疫调节物质的病理生产最小化，以增强受试者中恶性肿瘤的治疗控制来自癌症的方法，用于分析调控机制的物质的分析方法，用于分析的试剂盒，用于制备药物制剂的某些化合物的使用以及药物制剂。

4. 发明申请

US20070269441A1 Immunoregulation in cancer, chronic inflammatory and autoimmune diseases 审中-公开
标题翻译：癌症免疫调节，慢性炎症和自身免疫性疾病
公开(公告)号：US20070269441A1
公开(公告)日：2007-11-22
申请号：US11785821
申请日：2007-04-20
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： A61K39/395 , A61K47/00 , A61P35/00 , A61P37/00 , G01N33/535
CPC分类号： C07K16/18 , G01N33/6842 , G01N33/6851 , G01N2333/70546 , G01N2800/52
摘要： The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
摘要翻译：本发明主要涉及一种用于分析针对这些因素的免疫调节整联蛋白结合因子和/或患者内源性抗体的量的方法，该因子具有调节患有癌症或炎症或自身免疫的受试者的免疫功能的能力疾病，通过利用结合试剂来确定这些因素和/或针对这些因素的患者内源性抗体，由此可以确定患有癌症或炎性或自身免疫性疾病的受试者的任何治疗的预后和/或治疗功效和/或监控。本发明还涉及治疗活性化合物用于消除，抑制或增强用于制备用于治疗癌症，炎性病症或自身免疫疾病的药物的结合因子的用途。

5. 发明授权

US09120874B2 Methods of immunoregulation by albumin neo-structures 有权
标题翻译：白蛋白新结构免疫调节方法
公开(公告)号：US09120874B2
公开(公告)日：2015-09-01
申请号：US12599484
申请日：2008-05-08
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： A61K38/38 , C07K14/765 , C07K16/18 , A61K38/00 , A61K39/00
CPC分类号： C07K16/18 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K2317/34 , G01N33/5044 , G01N33/57484 , G01N2333/55 , G01N2333/765 , G01N2500/10
摘要： The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.
摘要翻译：本发明涉及对应于人组织中存在的通常存在的血清蛋白的细胞结合肽，片段，新结构和/或新表位的分离的蛋白质序列，其中所述肽，片段，新结构和/或新的表皮具有免疫调节活性，并且是组织或恶性肿瘤中增强的蛋白水解活性和/或构象变化的结果。在本专利申请中，已经鉴定出通过与免疫细胞上的受体结合而具有免疫调节活性的几种这些肽，片段，新结构和/或新表位的共同结构。本发明还涉及针对人组织中存在的正常存在的血清蛋白的细胞结合片段的单克隆和/或多克隆抗体，如上所述。

6. 发明授权

US08133688B2 Immunoregulation in cancer, chronic inflammatory and autoimmune diseases 有权
标题翻译：癌症免疫调节，慢性炎症和自身免疫性疾病
公开(公告)号：US08133688B2
公开(公告)日：2012-03-13
申请号：US13157215
申请日：2011-06-09
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： G01N33/53
CPC分类号： C07K16/18 , G01N33/6842 , G01N33/6851 , G01N2333/70546 , G01N2800/52
摘要： The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
摘要翻译：本发明主要涉及一种用于分析针对这些因素的免疫调节整联蛋白结合因子和/或患者内源性抗体的量的方法，该因子具有调节患有癌症或炎症或自身免疫的受试者的免疫功能的能力疾病，通过利用结合试剂来确定这些因素和/或针对这些因素的患者内源性抗体，由此可以确定患有癌症或炎性或自身免疫性疾病的受试者的任何治疗的预后和/或治疗功效和/或监控。本发明还涉及治疗活性化合物用于消除，抑制或增强用于制备用于治疗癌症，炎性病症或自身免疫疾病的药物的结合因子的用途。

7. 发明申请

US20110287969A1 IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES 有权
标题翻译：癌症免疫调节，慢性炎症和自身免疫性疾病
公开(公告)号：US20110287969A1
公开(公告)日：2011-11-24
申请号：US13157215
申请日：2011-06-09
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： C40B30/04 , G01N33/566
CPC分类号： C07K16/18 , G01N33/6842 , G01N33/6851 , G01N2333/70546 , G01N2800/52
摘要： The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
摘要翻译：本发明主要涉及一种用于分析针对这些因素的免疫调节整联蛋白结合因子和/或患者内源性抗体的量的方法，该因子具有调节免疫调节功能的能力。患有癌症或炎症或自身免疫性疾病的受试者通过利用结合试剂来确定这些因素和/或针对这些因素的患者内源性抗体，由此患有癌症的受试者的任何治疗的预后和/或治疗功效或炎性或自身免疫疾病可以被确定和/或监测。本发明还涉及治疗活性化合物用于消除，抑制或增强用于制备用于治疗癌症，炎性病症或自身免疫疾病的药物的结合因子的用途。

8. 发明申请

US20120219973A1 IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES 审中-公开
标题翻译：癌症免疫调节，慢性炎症和自身免疫性疾病
公开(公告)号：US20120219973A1
公开(公告)日：2012-08-30
申请号：US13411361
申请日：2012-03-02
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： G01N33/566
CPC分类号： C07K16/18 , G01N33/6842 , G01N33/6851 , G01N2333/70546 , G01N2800/52
摘要： The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
摘要翻译：本发明主要涉及一种用于分析针对这些因素的免疫调节整联蛋白结合因子和/或患者内源性抗体的量的方法，该因子具有调节免疫调节功能的能力。患有癌症或炎症或自身免疫性疾病的受试者通过利用结合试剂来确定这些因素和/或针对这些因素的患者内源性抗体，由此患有癌症的受试者的任何治疗的预后和/或治疗功效或炎性或自身免疫疾病可以被确定和/或监测。本发明还涉及治疗活性化合物用于消除，抑制或增强用于制备用于治疗癌症，炎性病症或自身免疫疾病的药物的结合因子的用途。

9. 发明申请

US20110262470A1 IMMUNOREGULATORY STRUCTURES FROM NORMALLY OCCURRING PROTEINS 有权
标题翻译：来自正常蛋白质的免疫组织结构
公开(公告)号：US20110262470A1
公开(公告)日：2011-10-27
申请号：US12599484
申请日：2008-05-08
申请人： Leif Hakansson , Birgitta Clinchy
发明人： Leif Hakansson , Birgitta Clinchy
IPC分类号： A61K39/00 , A61P37/06
CPC分类号： C07K16/18 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K2317/34 , G01N33/5044 , G01N33/57484 , G01N2333/55 , G01N2333/765 , G01N2500/10
摘要： The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.
摘要翻译：本发明涉及对应于人组织中存在的通常存在的血清蛋白的细胞结合肽，片段，新结构和/或新表位的分离的蛋白质序列，其中所述肽，片段，新结构和/或新的表皮具有免疫调节活性，并且是组织或恶性肿瘤中增强的蛋白水解活性和/或构象变化的结果。在本专利申请中，已经鉴定出通过与免疫细胞上的受体结合而具有免疫调节活性的几种这些肽，片段，新结构和/或新表位的共同结构。本发明还涉及针对人组织中存在的正常存在的血清蛋白的细胞结合片段的单克隆和/或多克隆抗体，如上所述。

10. 发明申请

US20120220470A1 DIAGNOSTIC METHOD FOR DETECTING CANCER BY MEASURING AMOUNT OF A CYTOKINE LIKE IL-6 审中-公开
标题翻译：通过测量细胞因子样IL-6检测癌症的诊断方法
公开(公告)号：US20120220470A1
公开(公告)日：2012-08-30
申请号：US13367132
申请日：2012-02-06
申请人： Leif Hakansson , Birgitta Clinchy , Rune Sjödahl
发明人： Leif Hakansson , Birgitta Clinchy , Rune Sjödahl
IPC分类号： C40B30/00 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/6863 , C07K14/52 , C07K14/5412 , G01N33/5047 , G01N33/5091 , G01N33/57488 , G01N2333/5412 , G01N2400/50
摘要： The present invention relates to a diagnostic method for predicting the possible recurrence of tumours in cancer patients. The method comprises culturing blood cells from a patient suffering from cancer in the presence of a cytokine stimulating factor, where after the amount of induced cytokine thereby produced is determined giving an indication of the risk of recurrence of the cancer.
摘要翻译：本发明涉及用于预测癌症患者肿瘤可能复发的诊断方法。该方法包括在细胞因子刺激因子存在下培养来自患有癌症的患者的血细胞，其中确定了由此产生的诱导的细胞因子的量，其给出了癌症复发风险的指征。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式